

AD \_\_\_\_\_

Award Number: DAMD17-99-2-9043

TITLE: Drug Development and Conservation in West and Central  
Africa/Performance of Neurochemical and Radio Receptor  
Assays of Plant Extracts

PRINCIPAL INVESTIGATOR: Deborah C. Mash, Ph.D.

CONTRACTING ORGANIZATION: University of Miami  
Miami, Florida 33136

REPORT DATE: September 2002

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20030203 063

**REPORT DOCUMENTATION PAGE**Form Approved  
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

<b>1. AGENCY USE ONLY (Leave blank)</b>		<b>2. REPORT DATE</b> September 2002	<b>3. REPORT TYPE AND DATES COVERED</b> Annual (1 Sep 01 - 31 Aug 02)	
<b>4. TITLE AND SUBTITLE</b> Drug Development and Conservation in West and Central Africa/Performance of Neurochemical and Radio Receptor Assays of Plant Extracts			<b>5. FUNDING NUMBERS</b> DAMD17-99-2-9043	
<b>6. AUTHOR(S)</b> Deborah C. Mash, Ph.D.				
<b>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</b> University of Miami Miami, Florida 33136  E-Mail: dmash@med.miami.edu			<b>8. PERFORMING ORGANIZATION REPORT NUMBER</b>	
<b>9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)</b> U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			<b>10. SPONSORING / MONITORING AGENCY REPORT NUMBER</b>	
<b>11. SUPPLEMENTARY NOTES</b>				
<b>12a. DISTRIBUTION / AVAILABILITY STATEMENT</b> Approved for Public Release; Distribution Unlimited.			<b>12b. DISTRIBUTION CODE</b>	
<b>13. ABSTRACT (Maximum 200 Words)</b>  none provided				
<b>14. SUBJECT TERMS</b>			<b>15. NUMBER OF PAGES</b> 6	
			<b>16. PRICE CODE</b>	
<b>17. SECURITY CLASSIFICATION OF REPORT</b> Unclassified		<b>18. SECURITY CLASSIFICATION OF THIS PAGE</b> Unclassified	<b>19. SECURITY CLASSIFICATION OF ABSTRACT</b> Unclassified	<b>20. LIMITATION OF ABSTRACT</b> Unlimited

## Table of Contents

<b>Cover.....</b>	<b>1</b>
<b>SF 298.....</b>	<b>3</b>
<b>Introduction.....</b>	<b>4</b>
<b>Body.....</b>	<b>4</b>
<b>Key Research Accomplishments.....</b>	
<b>Reportable Outcomes.....</b>	
<b>Conclusions.....</b>	
<b>References.....</b>	<b>6</b>
<b>Appendices.....</b>	

## ICBG PROGRESS REPORT 6/7/2002

### Specific Aims

The main objective of these studies was to study the CNS activity of these plant fractions using specific radio ligand binding assays to identify their selectivity profiles as well as to determine their functional activities as either a full or partial agonist or antagonist.

### Materials

The following table gives a list of the samples provided to us thus far.

Table 1: ICBG PLANT SAMPLES

In House Sample#	SU-Lab Number	Plant Part	Wt given (mg)
ICBG 1	SU1904	Whole Plnt	25
ICBG 2	SU1905	Sd Pulp	25
ICBG 3	SU1906	Pn polar	25
ICBG 4	SU1907	Lf/Stem	25
ICBG 5	SU1908	Lf/stem	25
ICBG 6	SU1909	Stbk	25
ICBG 7	SU1910	Stbk	25
ICBG 8	SU1911	Stbk	25
ICBG 9	SU1912	Whole Plnt	25
ICBG 10	SU1913	Whole Plnt	25
ICBG 11	SU1914	Ft pulp	25

### Methods

*Preparation of Extracts:* Stocks of the solid extracts were prepared by weighing 4 mg of sample and diluting to a total volume of 5 ml with 50% ethanol solvent for a final concentration of 0.8 mg/ml.

*Opioid Recetor(kappa-1) Ligand Binding<sup>a</sup>:* Two-point binding screens using [<sup>3</sup>H]U69593 were performed as per methods within the grant and previously (Izenwasser et al,1999). Briefly, mokey insular cortex was homogenized in ice-cold buffer (1:10 w/w, 50 mM Tris, 176  $\mu$ M MnCl<sub>2</sub>, 0.1% BSA pH 7.4), centrifuged at 32,000 x g for 10 minutes, and the supernatant was discarded. The pellet was resuspended (1:10, w/w) with buffer, and 100  $\mu$ l was added to each tube for a final concentration of 10.0 mg/ml (original tissue wet weight), in a final assay tube volume of 1.0 ml. Screens were performed by incubating 2 concentrations of extract (0.8 and 80

µg/tube) in the presence 1.0 nM of radioligand for 1 hr at 25°C, to determine their inhibitory potency (% inhibition). Nonspecific binding was determined by binding in the presence of 10 µM naloxone. Incubations were terminated by vacuum filtration through glass fiber filters (Whatman 934-AH) presoaked in 1% polyethylenimine (PEI) followed by washing with ice-cold buffer (2 x 5 ml).

*Norepinephrine Transporter (NET) Ligand Binding<sup>b</sup>*: Two-point binding screens using [<sup>3</sup>H]Nisoxetine were performed as per methods within the grant and previously (Tejani-Butt et al, 1990). Briefly, monkey hypothalamus was homogenized in ice-cold buffer (1:10 w/w, 50 mM Tris, 300 mM NaCl, 5 mM KCl pH 7.4), centrifuged at 32,000 x g for 10 minutes, and the supernatant was discarded. The pellet was resuspended (1:10, w/w) with buffer, and 100 µl was added to each tube for a final concentration of 10.0 mg/ml (original tissue wet weight), in a final assay tube volume of 1.0 ml. Screens were performed by incubating 2 concentrations of extract (0.8 and 80 µg/tube) in the presence 3.0 nM of radioligand for 4 hr at 4°C, to determine their inhibitory potency (% inhibition). Nonspecific binding was determined by binding in the presence of 10 µM Mazindol. Incubations were terminated by adding 4ml of ice-cold buffer and vacuum filtration through glass fiber filters (Whatman 934-AH) presoaked in 0.5% polyethylenimine (PEI) followed by washing with ice-cold buffer (2 x 4 ml).

*Data Analysis*: Data are analyzed using the non-linear regression algorithms found in EBDA/LIGAND™ and GraphPad Prism™ computer software programs.

## Results.

Table 2: Plant Extract Activity (% inhibition) on DAT, SERT, Mµ, Kappa-1 & NET

In House Sample#	DAT ([ <sup>3</sup> H]WIN35,428)		SERT ([ <sup>125</sup> I]RTI-55)		Mµ ([ <sup>3</sup> H]DAMGO)		Kappa-1 ([ <sup>3</sup> H]U69593)		Kappa-1 ([ <sup>3</sup> H]U69593)	
	@ 0.8 µg/tube	@ 80 µg/tube	@ 0.8 µg/tube	@ 80 µg/tube	@ 0.8 µg/tube	@ 80 µg/tube	@ 0.8 µg/tube	@ 80 µg/tube	IC50 Ug/ml	nH
ICBG 1	--	58.7	--	42.0	1.8	60.4	--	84.0	37.4	1.21
ICBG 2	--	46.3	--	90.1	16.7	60.2	--	91.1	15.9	0.93
ICBG 3	--	18.8	--	46.7	31.8	39.4	--	78.8	51.6	1.32
ICBG 4	--	77.7	--	--	33.0	41.0	--	82.1	72.6	1.25
ICBG 5	--	22.9	--	--	--	33.3	--	--	N/A	
ICBG 6	--	27.2	--	20.5	--	33.4	--	51.6	68.6	1.49
ICBG 7	--	--	--	--	--	29.6	--	9.9	N/A	
ICBG 8	--	50.6	--	31.0	10.3	29.2	--	64.0	44.9	1.04
ICBG 9	--	82.0	--	--	--	32.8	--	64.0	81.8	1.13
ICBG 10	--	74.9	3.9	76.1	28.6	32.9	--	74.5	47.8	1.11
ICBG 11	--	--	--	87.2	32.4	47.1	--	41.1	N/A	

-- denotes no inhibitory activity

As can be seen in Table 2, a number of extracts inhibited greater than 50% of the binding at DAT, SERT and Mµ. Therefore, full characterization of these compounds will be conducted.

## Future Aims

Future studies will be to further characterize those extracts found to be active with full competition curves. In addition we plan to expand the screens with other ligands specific to other neuroreceptors and neurotransmitters, and adding new compounds as made available.

#### References

<sup>a</sup>Sari Izenwasser, Julie K. Staley, Stephanie Cohn, and Deborah C. Mash. Characterization of Kappa-Opioid Receptor Binding in Human Insular Cortex. *Life Sciences* 1999; **65**(9):857-862.

<sup>b</sup>Shanaz M, Tejani-Butt, David J, Brunswick and Alan Frazer. [<sup>3</sup>H]Nisoxetine: a new radioligand for norepinephrine uptake sites in brain. *European Journal of Pharmacology* 1990; **191**:239-243.